Related Experiment Video
Updated: Apr 4, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic
Nawar Diar Bakerly1, Ashley Woodcock2, John P New3
1Salford Royal NHS Foundation Trust, Salford, UK. nawar.bakerly@srft.nhs.uk.
Background:
New treatments need to be evaluated in real-world clinical practice to account for co-morbidities, adherence and polypharmacy.
Methods:
Patients with chronic obstructive pulmonary disease (COPD), ≥ 40 years old, with exacerbation in the previous 3 years are randomised 1:1 to once-daily fluticasone furoate 100 μg/vilanterol 25 μg in a novel dry-powder inhaler versus continuing their existing therapy. The primary endpoint is the mean annual rate of COPD exacerbations; an electronic medical record allows real-time collection and monitoring of endpoint and safety data.
Conclusions:
The Salford Lung Study is the world's first pragmatic randomised controlled trial of a pre-licensed medication in COPD.
Trial Registration:
Clinicaltrials.gov identifier NCT01551758.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

